[Etiology of community-acquired lower urinary infections and antimicrobial resistance of Escherichia coli: a national surveillance study]

Med Clin (Barc). 2008 Apr 12;130(13):481-6. doi: 10.1157/13119488.
[Article in Spanish]

Abstract

Background and objectives: The increasing rates of resistance exhibited by uropathogens represent a serious problem. The aim of this study was to determine, in Spain, the etiology of community-acquired lower urinary infections and antimicrobial resistance of Escherichia coli isolates.

Methods: Prospective multicenter study conducted between February and June 2006, in 15 microbiology laboratories located in 9 autonomous regions.

Results: A total of 3,109 isolates were recovered. E. coli was the most frequent (70.8%), followed by Klebsiella spp (6.8%) Proteus spp (6.6%), and Enterococcus spp (5.5%). The resistant rate of E. coli for phosphomycin was 1.7%, 3.8% nitrofurantoin, 6.9% cefexime, 8.1% amoxicillin-clavulanic, 8.9% cefuroxime, and 23.9% ciprofloxacin. The 5.2% were extended-spectrum beta-lactamase (ESBL)- producing microorganisms. Resistance of E. coli to ciprofloxacin was lower in people younger than 40 years (6.7% vs 33.9% in > 60, p < 0.001), and in some regions (12.5% in Galicia vs 37.3% in Valencia). ESBL-producing E.coli was higher in people older than 60 years (79.1% vs 7% in < 40, p < 0.001), and exhibited geographic variations (18.4% in Valencia, 0.8% in Galicia). The 68.6% of ESBL-producing E.coli were resistant to cotrimoxazole, 72.2% to ciprofloxacin vs 10.6% to nitrofurantoin and 1.9% to phosphomycin.

Conclusions: The increasing rates of resistance and cross-resistance of this study make evident a real problem that strengthens the need for a reevaluation of the empiric treatment of lower urinary infections.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Anti-Bacterial Agents / therapeutic use*
  • Community-Acquired Infections* / drug therapy
  • Community-Acquired Infections* / epidemiology
  • Community-Acquired Infections* / microbiology
  • Drug Resistance, Microbial*
  • Escherichia coli / isolation & purification*
  • Escherichia coli Infections* / complications
  • Escherichia coli Infections* / drug therapy
  • Escherichia coli Infections* / epidemiology
  • Female
  • Humans
  • Male
  • Middle Aged
  • Prevalence
  • Sex Distribution
  • Spain / epidemiology
  • Surveys and Questionnaires*
  • Urinary Tract Infections* / drug therapy
  • Urinary Tract Infections* / epidemiology
  • Urinary Tract Infections* / microbiology

Substances

  • Anti-Bacterial Agents